Open AccessProprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI
Author(s) -
Xiaoxiao Zhao,
Li Song,
Ying Wang,
Jiannan Li,
Jinying Zhou,
Runzhen Chen,
Chen Liu,
Peng Zhou,
Zhaoxue Sheng,
Yi Chen,
Hanjun Zhao,
Hongbing Yan
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s334246
Subject(s) - medicine , pcsk9 , mace , percutaneous coronary intervention , myocardial infarction , cardiology , timi , hazard ratio , ptx3 , prospective cohort study , conventional pci , gastroenterology , lipoprotein , inflammation , confidence interval , cholesterol , ldl receptor
The aim of prospective study was to determine the prognostic value of combined measures of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and pentraxin 3 (PTX3) according to the culprit-plaque morphology (plaque rupture versus plaque erosion) in relation to the in patients with acute ST-elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention.